Choice Choi

I`m an AI and Robot Town developer in VN.

[Choice Choi @ChoiceChoi3]

Finally, $NANOX officially announced its offline participation in #RSNA.

It has been a long time since I decided to invest in $NNOX.

The reason why I chose it as a retirement item is because the founder suddenly died of liver cancer amid suspicions of scams due to numerous bad reviews, malicious criticism, and responsibility that was not shown in time,,,

It is also because I visited Yongin Fab twice in 2022 and 2023 and confirmed the actual operation of the cold cathode, but it is also because I recognized the reality that many people who were fighting for their lives during the pandemic and unfortunately passed away, and many people who are still suffering from aftereffects are being bombarded with excessive radiation CT, but there is no proper solution, and they are continuously being attacked by radiation even at a level where they cannot tell whether it is a disease or a medicine, and are undergoing in-depth diagnosis.

#Nanox's next version Arc-X is without a doubt the first step to realize the grand ambition, but the management should report a thousand times more honestly than the founder, and should not repeat the incident of replacing the nonsensical staff who opportunistically talk nonsense and deceiving investors with unmaintainable timelines.

If cost-effective, affordable low-dose lung diagnosis is made, a realistic foundation for creating a public health market will be newly formed, and all the health institutions in the world will have to think together and implement a policy to encourage early diagnosis and progress monitoring solutions for chronic diseases nationwide.

$Nanox's only competitive edge is the real end-user, medical finance and insurance (Reimbursement) reduction, which is a breakthrough, and there are great expectations.

With the confidence that it will become a national and global low-power safety solution for excessive medical expenses, we hope that this first RSNA participation will change the image to a new approach of low-dose, low-power, low-price, but with the highest quality service.

picture source: Effectiveness of COVID-19 Vaccines Over Time Against Clinical and Radiologic Outcomes Related to Severe SARS-CoV-2 Infection

[Choice Choi @ChoiceChoi3]

$NNOX

https://t.co/RBhaDdZyvw

[kinghano10000 @oZChlEQ9frKMQlt]

$nnox $ai
Big news from #ECR2026!

We're honored and excited to share that Nanox has been named #ECR 2026 Newcomer of the Year!
Thank you to the European Congress of Radiology and to everyone who continues to support innovation in healthcare.

[kinghano10000 @oZChlEQ9frKMQlt]

$NNOX #InvestorRelations #tomosynthesis $ai #mbx
RSNA Innovation theater with Dr. Orit Wimpfheimer 2025
https://t.co/61LQoRLCDa

[Choice Choi @ChoiceChoi3]

$NNOX 2026 Full Year Guidance: $35M
Based on the "Pre-Orders".

#Arc-X mass production: hundreds of units are in progresses

#IntuitiveSurgical was once a penny stock too. Now? The undisputed king of robotic surgery.

What they share:
Multi-year manufacturing partnership with #FABRINET Precision robotics engineering capability

Penny stock → Market dominator
The #ISRG story.

The $NNOX story in progress.
History rhymes.

[Choice Choi @ChoiceChoi3]

$NNOX
$NANOX
This is the world's most advanced X-ray source revolution, and the evidence silences its critics.

It's all true, and I'm basing it on facts.
This is the world's most advanced X-ray source revolution,
and the evidence that silences its critics.

It's all true, and it's based on facts.

And that's not even all. It's just a part of it.

[Choice Choi @ChoiceChoi3]

$NNOX $NANOX
TAP2D superiority

[Choice Choi @ChoiceChoi3]

Those who spent years claiming " $NNOX MEMS doesn't work" are now watching #Varex integrate it into their flagship platform while their preferred CNT technology faces FDA scrutiny.

The silence from the critic camp speaks volumes.

[Choice Choi @ChoiceChoi3]

$NNOX
$NANOX

[Choice Choi @ChoiceChoi3]

Although $Nanox has yet to officially announce its Mammo market entry, allowing its many critics to see the truth, having studied $NNOX for over five years,
I can confidently present the table below with sufficient evidence and facts.

Nanox's mammography/DBT market entry is strategically feasible.

Cold Cathode Multi-Source Technology provides an exclusive competitive advantage that major OEMs cannot replicate.
Direct MSaaS + OEM Partnership Hybrid Strategy.

This clearly demonstrates that management is already preparing for explosive growth in addition to exponential growth in Q3 2025.

[Choice Choi @ChoiceChoi3]

Although $Nanox has yet to officially announce its Mammo market entry, allowing its many critics to see the truth, having studied $NNOX for over five years,
I can confidently present the table below with sufficient evidence and facts.

Nanox's mammography/DBT market entry is strategically feasible.

Cold Cathode Multi-Source Technology provides an exclusive competitive advantage that major OEMs cannot replicate.
Direct MSaaS + OEM Partnership Hybrid Strategy.

This clearly demonstrates that management is already preparing for explosive growth in addition to exponential growth in Q3 2025.

[Choice Choi @ChoiceChoi3]

Those who spent years claiming " $NNOX MEMS doesn't work" are now watching #Varex integrate it into their flagship platform while their preferred CNT technology faces FDA scrutiny.

The silence from the critic camp speaks volumes.

[Choice Choi @ChoiceChoi3]

https://t.co/TDiUymRLsx
After completing field testing and clinical validation of product lineup (durability - performance, degradation defense mechanisms)

$NANOX appear to be beginning full-scale marketing and promotion.
$NNOX

#Arc-X
Tube (and Chip) OEM - All Industries
AI Solutions

Three years late to launch,
but three years early

It will dominate the global market.

[Choice Choi @ChoiceChoi3]

$Nanox.ARC - X
$NNOX 2025 RSNA

[Choice Choi @ChoiceChoi3]

How rapidly will $NANOX grow in 2026 and 2027?

Counting backwards,
$NNOX's quarterly BEP threshold is approximately $26 million to $30 million.

Accounting for rising administrative expenses, operating profit is estimated to be around 35-40%,
passing the break-even point.

Management has publicly stated that this represents a profit for the quarter of 2027.

Based on Q3 2025, when quarterly sales peaked at $3.4 million,
Nanox should achieve ~10x its current sales between Q2 and Q3 2027.

And to quickly reach $1 billion in quarterly sales,
"lung cancer" is not a plan; it's an ongoing process.

,,,,

[Choice Choi @ChoiceChoi3]

What I learned during the $NNOX feasibility study,

Despite the complete lack of recognition for 2D CXR as a equip for early "lung cancer screening",
approximately "33 million" cases are being performed annually, wasting valuable funds.

When $NANOX receives #TAP2D approval and becomes a standalone device,

the #Arc-X will creates a significant contribution,
while also reducing the cost of duplicate scans.

Even in terms of CapEx, the 3D tomosynthesis Arc-X, including end-to-end services, was found to be cheaper than the 2D CXR equipment + options.

[Choice Choi @ChoiceChoi3]

$NANOX Arc-X,
2026 "$35M" Revenue Confirmed Guidance Background
I reviews the guidance based on the official announcement.

If we divide $35M into four quarters,
each quarter will be over $8.5M.

6+7+8+9 = only 30
7+8+9+10 = 34, which is not yet 35.

In response to a panelist's question about the basis for the 35 figure,
$NNOX CEO clearly stated that it was based on "pre-orders."

Given the extremely conservative nature of Jews,
I predict a figure of around ~50.

In keeping with their instinct for cliff-edge tug-of-war,
I expect they will lead many partners with the courage to say,
"I don't care if you don't do it."

Around *35-40*
Quarterly sales of $10 million,
quarterly loss damage of less than $10 million
When Golden Crossed
Losses will begin to decrease rapidly, and sales and profits will increase significantly.

I expect a small snowball to begin rolling.

[Choice Choi @ChoiceChoi3]

$Nanox.ARC - X
$NNOX
Cold Cathode with breakthrough imaging technology.

[Choice Choi @ChoiceChoi3]

https://t.co/WFmskrOtx6

$NANOX Arc-X
$NNOX

[Choice Choi @ChoiceChoi3]

https://t.co/6x4OvA8yM9

$NANOX Arc-X
$NNOX